Cue reactivity and opioid blockade in amphetamine dependence: A randomized, controlled fMRI study

Amphetamine use disorder is a global health problem for which there is still no approved pharmacological treatment. In Northern Europe, amphetamine has dominated injection drug use for decades (Hakansson et al., 2009). One of the few promising pharmacological treatments for amphetamine dependence is the opioid antagonist naltrexone (Karila et al., 2010), which is currently used clinically for the treatment of alcohol and opioid dependence (Lobmaier et al., 2011; R ösner et al., 2010). In a number of human laboratory studies, it has consistently been shown that pre-treatment with naltrexone attenuates the subjective effects of amphetamine (Jayaram-Lindström et al., 2004, 2008b; Marks et al., 2014; Ray et al., 2015).

Source: Drug and Alcohol Dependence - July 26, 2018 Category: Addiction Authors: Joar Guterstam, Nitya Jayaram-Lindstr öm, Jonathan Berrebi, Predrag Petrovic, Martin Ingvar, Peter Fransson, Johan Franck Tags: Full length article Source Type: research